Related Experiment Videos
Structural changes in the kidney induced by coarctation hypertension.
M P De Bruno1, Turoni CMJ, R O Marañón
1Department of Physiology, INSIBIO-National University of Tucumán, Argentina. peralmaria@hotmail.com
Summary
Hypertension in rats caused kidney structural changes, including hypertrophy and glomerulosclerosis in the non-ischemic kidney. Losartan treatment partially reversed these alterations, suggesting a role for angiotensin II in the disease process.
Area of Science:
- Nephrology
- Cardiovascular Research
- Pathology
Background:
- Aortic coarctation leads to hypertension, causing significant renal structural changes.
- The non-ischemic kidney (NIK) in hypertensive rats exhibits morphological and histological alterations.
- Understanding these changes is crucial for managing hypertensive kidney disease.
Purpose of the Study:
- To investigate structural changes in the non-ischemic kidney (NIK) of hypertensive rats.
- To evaluate the effect of losartan on these renal alterations.
- To explore the role of angiotensin II in mediating NIK damage.
Main Methods:
- Comparison of hypertensive rats (HR) with sham-operated rats (SR).
- Administration of losartan (LOS) to assess its therapeutic effects.
- Morphological and histological examination of renal tissues, including stereological analysis of afferent arterioles.
- Assessment of mean arterial pressure (MAP) and kidney weight.
Main Results:
- Hypertensive rats showed elevated MAP and NIK hypertrophy (increased weight).
- Losartan reduced MAP but did not fully normalize it, nor did it revert NIK hypertrophy.
- NIK in hypertensive rats exhibited glomerulosclerosis, mesangial proliferation, and arteriolar thickening, which were partially reverted by losartan.
- Stereological analysis revealed afferent arteriolar hypertrophy and increased wall/lumen ratio in NIK, with losartan diminishing wall thickness.
Conclusions:
- Hypertension induces significant structural damage in the non-ischemic kidney.
- Losartan partially reverses NIK damage, suggesting angiotensin II's role in glomerulosclerosis, mesangial proliferation, and arteriosclerosis.
- These findings highlight potential therapeutic targets for hypertensive kidney disease.